长期便秘对Bifidobacterium longum CCFM1112的影响:一个随机,双盲,安慰剂控制的随机研究
1State Key Laboratory of Food Science and Technology, 66374Jiangnan University, Wuxi, Jiangsu, China.
益生菌Bifidobacterium longum CCFM1112通过改善肠道微生物群和便的一致性,有效缓解慢性便秘. 这项研究表明,它作为一种天然治疗便秘的疗法具有潜力.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 营养科学 营养科学
背景情况:
- 益生菌在通过影响肠道微生物群来控制便秘方面表现有前途.
- 益生菌减轻便秘的确切机制需要进一步研究.
研究的目的:
- 评估Bifidobacterium longum (B. longum) CCFM1112在治疗慢性便秘方面的临床疗效.
- 探索B. longum CCFM1112对肠道微生物群组成和代谢概况的影响.
主要方法:
- 一项为期4周的随机,双盲,安慰剂对照研究,涉及56名患有慢性便秘的志愿者.
- 评估自发性排便,便的一致性 (布里斯托尔便形状量表) 和生活质量问卷 (PAC-SYM,PAC-QOL).
- 使用元基因组测序和非向代谢学来分析肠道微生物群和代谢物.
主要成果:
- 在患有慢性便秘的患者中,B. longum CCFM1112显著改善了生活质量 (PAC-QOL) 和便一致性 (BSFS).
- 益生菌的干预导致了肠道细菌的丰富性增加,这些细菌属包括Blautia,Anaerobutyricum和Streptococcus.
- 便中的利诺基酸,胺黄油酸 (GABA) 和花酸水平升高,以及血清代谢物的变化.
结论:
- 长菌 (Bifidobacterium longum CCFM1112) 在缓解慢性便秘症状方面表现出临床疗效.
- 益生菌调节肠道微生物群的组成和特定的代谢途径,有助于其有益的影响.
- B. longum CCFM1112为治疗慢性便秘提供了一个潜在的治疗策略.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
